

Image 6P1614

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
0994.00133

In Re Application Of: Katti, et al

DEC 22 2003

Serial No.  
10/019,192

Filing Date  
06/20/2002

Examiner  
Krass, Frederick, F.

Group Art Unit  
1614

Title: **GOLD CONTAINING CHEMOTHERAPEUTIC AGENTS**

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☒ the fee set forth in 37 CFR 1.17(p).

12/31/2003 DTESSEM1 00000016 10019192

01 FC:1806

180.00 OP

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
0994.00133

In Re Application: *1 P. Kanti, et al.*

Serial No.  
10/019,117

Filing Date  
06/20/2002

Examiner  
Krass, Frederick, F.

Group Art Unit  
1614

**GOLD CONTAINING CHEMOTHERAPEUTIC AGENTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed:
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited **December 19, 2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence  
Marie M. DeWitt

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
Signature

Dated: \_\_\_\_\_

CC:



# MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)  
Sheet 1 of 1

<b>PTO-1449</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>				Docket Number (Optional) <b>0994.00133</b>		Application Number <b>10/019,192</b>	
				Applicant <b>Kattesh V. Katti, et al.</b>			
				Filing Date <b>06/20/02</b>		Group Art Unit <b>1614</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLAS S	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCKET NUMBER	DATE	COUNTRY	CLAS S	SUBCLASS	TRANSLATION	
						YES	NO
<b>OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)</b>							
	Berglof, F.E., et al., "Auranofin: an Oral Chrysotherapeutic Agent for the Treatment of Rheumatoid Arthritis," <i>J. Rheumatol.</i> , 5, 68 (1978).						
	Berning, D.E., et al., "In Vitro and In Vivo Characterization of a <sup>99m</sup> Tc Complex with Tris(hydroxymethyl)phosphine (THP), "Hyroxymethyl bis(phosphines) and their palladium(II) and platinum(II) complexes formed via biphasic reactions. Crystal structure of [Pd(HOH <sub>2</sub> C) <sub>2</sub> PC <sub>6</sub> H <sub>4</sub> P(CH <sub>2</sub> OH) <sub>2</sub> ] <sub>2</sub> CL <sub>2</sub> Nucl. <i>Med. Biol.</i> , 23, 617 (1996).						
	Fricker, S.P., "Medicinal chemistry and pharmacology of gold compounds," <i>Transition Met, Chem</i> , 21, 377 (1996).						
	Katti, K.V., "Recent advances in the chemistry of water-soluble phosphines - Catalytic and biomedical aspects," <i>Curr. Sci.</i> , 70, 219 (1996).						
	Mirabelli, C.K., et al., "Evaluation of the <i>In Vivo</i> Antitumor Activity and <i>In Vitro</i> Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models," <i>Cancer Res.</i> , 45, 32 (1985).						
	Reddy, V.S., et al., "Chemistry in Environmentally Benign Media." <i>Inorg. Chem.</i> , 35, 1753 (1996).						
	Reddy, V.S., et al., <i>Inorg. Chem. Acta.</i> , 240, 367 (1995).						
	Reddy, V.S., et al., <i>J. Chem. Soc. Dalton Trans.</i> , 1301 (1996).						
	Schubiger, P.A., et al., "Vehicles, Chelators, and Radionuclides: Choosing the "Building Blocks" of an Effective Therapeutic Radioimmunoconjugate," <i>Bioconjugate Chem.</i> , 7, 165 (1996).						
	Shi, J.C., et al., "Chiral Phosphine Ligands Derived from Sugars. <i>Inorg. Chem.</i> , 35, 2742 (1996).						
	Simon, et al, "Screening Trial with the Coordinated Gold Compound Auranofin Using Mouse Lymphocytic Leukemia P388 <sup>1</sup> ," <i>Cancer Res.</i> , 41, 94 (1981).						
	Volkert, W.A., et al., "Therapeutic Radionuclides: Production and Decay Property Considerations," <i>J. Nucl. Med.</i> , 32, 174 (1991).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE